首页> 外文期刊>Hepatic oncology. >When to consider liver transplantation in hepatocellular carcinoma patients?
【24h】

When to consider liver transplantation in hepatocellular carcinoma patients?

机译:何时考虑肝细胞癌患者的肝移植?

获取原文
获取原文并翻译 | 示例
           

摘要

Orthotopic liver transplantation (LT) has been regarded as the best cure among the three curative treatment modalities. However, when to consider LT in hepatocellular carcinoma (HCC) patients remains a complicated clinical question. In this article, we will look into the recent updates in the context of LT for HCC, including the timing of orthotopic LT (primary or salvage LT), patient selection criteria, newer prognostic markers and scoring systems, down-staging and bridging therapy, salvage LT and treatment option of post-LT HCC recurrence. Evolution of immunosuppressive therapy and future development of the LT for HCC will also be discussed.
机译:在三种治疗方法中,原位肝移植被认为是最好的治疗方法。然而,在肝细胞癌(HCC)患者中考虑LT仍然是一个复杂的临床问题。在这篇文章中,我们将探讨肝癌肝移植的最新进展,包括原位肝移植(原发性肝移植或挽救性肝移植)的时机、患者选择标准、较新的预后标志物和评分系统、下行分期和桥接治疗、挽救性肝移植和肝移植后肝癌复发的治疗选择。还将讨论免疫抑制疗法的演变和肝细胞癌LT的未来发展。

著录项

  • 来源
    《Hepatic oncology.》 |2017年第4期|共10页
  • 作者

    Ka Wing Ma; Tan To Cheung;

  • 作者单位

    Department of Surgery Queen Mary Hospital the University of Hong Kong Hong Kong;

    Department of Surgery Queen Mary Hospital the University of Hong Kong Hong Kong;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号